louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00632580: Intra- Versus Extraarticular Injection of Ropivacaine in Total Knee Arthroplasty
Official title: Intraartikulær Versus ekstraartikulær Bolus Injektion Med Ropivacain Ved Total knæalloplastik: et Prospektivt, Randomiseret, Dobbeltblindet, Kontrolleret Studie
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Pain, Postoperative
Keywords: Pain, Postoperative
Lead sponsor: Hvidovre University Hospital
Sponsor class: OTHER
First posted: 2008-03-10
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the optimal site for application of local anesthetics in total knee arthroplasty surgery. The hypothesis is, that improved pain relief is obtained when administering local anesthetics in the tissues sourrounding the knee joint compared to the knee joint itself.


Eligibility criteria: Inclusion Criteria:

* eligible for elective total knee arthroplasty
* able to speak and understand Danish
* able to give informed consent

Exclusion Criteria:

* alocohol or medical abuse
* allergies to local anesthetics
* age \< 18 yrs.
* intolerance to opioids

Primary outcomes:
measure: pain
timeFrame: 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Hvidovre University Hospital
Study officials:
affiliation: Hvidovre University Hospital
name: Lasse Andersen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01759680: Effects of 3 Months of Controlled Whole Body Vibrations on the Risk of Falls Among Nursing Home Residents
Official title: Effects of 3 Months of Controlled Whole Body Vibrations With Low Exposure Period on the Risk of Falls Among Nursing Home Residents
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Falls
Keywords: Risk of falls
Whole Body Vibration
Nursing Home
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2013-01-03
Enrollment: 62
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Tiredness, lack of motivation and low compliance can be observed in nursing home residents during the practice of physical activity. Because exercises should not be too vigorous, whole body vibration could potentially be an effective alternative.

The objective of this randomized controlled trial is to assess the impact of 3-month training by whole body vibration on the risk of falls among nursing home residents.

Patients were randomized into two groups: the whole body vibration group which received 3 training sessions every week composed of 5 series of only 15 seconds of vibrations at 30 Hz intensity and a control group with normal daily life for the whole study period.

The impact of this training on the risk of falls was assessed blindly by three tests: the Tinetti Test, the Timed Up and Go test and a quantitative evaluation of a 10-second walk performed with a tri-axial accelerometer.


Eligibility criteria: Inclusion Criteria:

* Resident of nursing home
* Able to move

Exclusion Criteria:

* weighing more than 150 kg
* having electronic implants (e.g. pacemaker, brain stimulators)
* having prosthetic hips or knees
* suffering from epilepsy, bleeding disorders, inflammatory abdominal disorders or at high risk of thromboembolism.

Primary outcomes:
measure: Risk of fall
timeFrame: 3 months
Secondary outcomes:
measure: Risk of fall evaluated by the Timed up and Go test
timeFrame: 3 months
measure: Risk of falls evaluated by the Locometrix
timeFrame: 3 months
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: University of Liège
Study officials:
affiliation: University Of Liège, Department of Public Health, Epidemiology and Health Economics, Liège, Belgiulm
name: Olivier Bruyère, PhD
role: STUDY_DIRECTOR
References:
citation: Beaudart C, Maquet D, Mannarino M, Buckinx F, Demonceau M, Crielaard JM, Reginster JY, Bruyere O. Effects of 3 months of short sessions of controlled whole body vibrations on the risk of falls among nursing home residents. BMC Geriatr. 2013 May 6;13:42. doi: 10.1186/1471-2318-13-42.
Clinical trial NCT06507280: The Effects of Periodontal Therapy on Gingival Crevicular Fluid NLRP3,Caspase-1,IL-1β Levels in Children With Gingivitis
Official title: The Effects of Periodontal Therapy on Gingival Crevicular Fluid NLRP3,Caspase-1,IL-1β Levels in Children With Gingivitis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Gingivitis
Keywords: NLRP3
CASPASE-1
IL-1β
GINGIVITIS
GCF
Lead sponsor: Aydin Adnan Menderes University
Sponsor class: OTHER
First posted: 2024-07-18
Enrollment: 60
Sex: ALL
Minimum age (years): 11
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: This study aims to determine the levels of NLRP3, caspase-1 and IL-1β concentrations in the gingival crevicular fluid of paediatric patients with gingivitis and their changes after periodontal treatment.

Detailed description: After being informed about the study and potential risks, necessary periodontal measurements will be performed and gingival crevicular fluid will be collected from all patients who gave written informed consent, and patients with gingivitis will be followed up on the 7th and 30th day after periodontal treatment.

Eligibility criteria: Inclusion Criteria:

Inclusion criteria for the group with gingivitis;

* Systemically healthy
* 11-14 years old
* Permanent dentition
* No need for endodontic and restorative treatment
* Gingivitis with gingivitis
* Have verbally and in writing agreed to participate in the study and are willing to attend follow-up appointments regularly participants will be included in the study.

Inclusion criteria for the healthy group;

* Systemically healthy
* 11-14 years old
* Permanent dentition
* No need for endodontic and restorative treatment
* Periodontally healthy
* Have verbally and in writing agreed to participate in the study and are willing to attend follow-up appointments regularly participants will be included in the study.

Exclusion Criteria

* In need of endodontic and restorative treatment
* Systemically unhealthy
* Patients who do not give verbal or written consent

Primary outcomes:
measure: NLRP3
timeFrame: Baseline
measure: Caspase-1
timeFrame: Baseline
measure: IL-1 Beta
timeFrame: Baseline
Secondary outcomes:
measure: NLRP3
timeFrame: 7. days - 30. days
measure: Caspase-1
timeFrame: 7. days -30. days
measure: IL-1 Beta
timeFrame: 7. days-30. days
Other outcomes:
Locations:
city: Aydın
country: Turkey
facility: Sultan Keles
Study officials:
References:
Clinical trial NCT01568580: Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
Official title: Open-label, Non-comparative, Multicenter, Phase III for Evaluation of Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Previously Treated Patients With Hemophilia A
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hemophilia A
Keywords: Hemophilia A
Factor VIII
Recombinant
Lead sponsor: GC Biopharma Corp
Sponsor class: INDUSTRY
First posted: 2012-04-02
Enrollment: 71
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to study the evaluation of efficacy and safety of GreenGene (Recombinant Factor VIII).


Eligibility criteria: Inclusion Criteria:

* Hemophilia A patients at least 12 years of age
* At least 150 treatment exposure-days to previous FVIII products
* FVIII≤2% at screening or diagnosis (FVIII≤1% for PK study)
* CD4 Lympocyte cell count\>400/㎕
* Patients willing to cooperate for the study
* Patient's or legal guardian's consent to participate in the study

Exclusion Criteria:

* FVIII inhibitor(neutralizing antibody to FVIII)≥0.6 Bethesda Units
* Coagulation disorders other than hemophilia A (e.g. Idiopathic Thrombocytopenic Purpura, von Willebrand Disease)
* Platelet count≤100,000㎣
* Subjects with clinical evidence of symptomatic HIV disease regardless of HIV-seroposive/seronegative
* Subjects with rFVIII antibody, mouse IgG antibody, or CHO antibody
* Creatinine levels more than 2 times of reference rage, GOT and GPT levels more than 3 times of reference range, diabetes mellitus or other metabolic disorder
* Subjects with diastolic blood pressure≥100mmHg not controlled with antihypertensive medications
* Anemia(hemoglobin\<12g/dL)
* Subjects with severe or life-threatening bleeding just before entry into the trial
* Subjects with a history of treatment failure due to formation of inhibitor to FVIII
* Subjects with a history of severe hypersensitive reactions to FVIII concentrate
* Subjects requiring pre-medication for FVIII infusion(e.g. antihistamines, etc)

Primary outcomes:
measure: Physician's assessment of hemostatic effect for on-demand treatment
timeFrame: 12 months
measure: Hemostatic effect for major bleeding
timeFrame: up to 1 year
Secondary outcomes:
measure: consumption amount of test drug
timeFrame: up to 12 month or 100 exposure days
measure: Subject's self assessment of treatment
timeFrame: 12 months
measure: FVIII Recovery(%)
timeFrame: every 3 months
measure: FVIII inhibitor incidence rate
timeFrame: every 3 months
measure: The number of adverse events
timeFrame: up to 1 year
measure: Surgery study: prohylactic effects
timeFrame: up to 1 year
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04407780: Cardio-Oncology Registry
Official title: Cardio-Oncologie: étude Pilote évaluant la faisabilité, Utilité Concrète, Interdisciplinaire d'Une Unité Spécialisée
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cancer
Cardiac Disease
Metabolic Syndrome
Arrhythmia
Heart Diseases
Keywords: cancer
heart
cardiovascular
cardio-oncology
onco-cardiology
phamacology
precision medicine
Lead sponsor: European Georges Pompidou Hospital
Sponsor class: OTHER
First posted: 2020-05-29
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All prosepctive patients seen in the cardio-oncology clinic. Observational data will be collected from the medical records. Outcomes measures according to scheduled follow-up visits for their cardiovascular health.

Brief summary: Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias.

CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt.

The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.


Eligibility criteria: Inclusion Criteria:

* referred to cardio-oncology

Exclusion Criteria:

* refusal to participate

Primary outcomes:
measure: Incidence of cardio-toxicty
timeFrame: 5 years
Secondary outcomes:
measure: Analysis of cardiotoxicity
timeFrame: 5 years
measure: Analysis of cardioprotective strategies
timeFrame: 5 years
measure: Analysis of underlying cardiovacsular profile
timeFrame: 5 years
measure: Analysis of arrhythmias
timeFrame: 5 years
measure: Precision medicine
timeFrame: 5 years
measure: Oncology
timeFrame: 5 years
measure: Cardiovascular outcomes
timeFrame: 10 years
measure: Any advserse event
timeFrame: 5 years
measure: Behaviour
timeFrame: 5 years
measure: Metabolic
timeFrame: 5 years
Other outcomes:
Locations:
city: Paris
country: France
facility: Assistance Publique Hôpitaux de Paris - Centre Université de Paris
Study officials:
References:
Clinical trial NCT02065180: The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome
Official title: The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypercholesterolaemia
Lead sponsor: Universiteit Antwerpen
Sponsor class: OTHER
First posted: 2014-02-17
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This randomised controlled trial studies the effect of a commercially available nutritional supplement on cholesterol levels in people with metabolic syndrome and elevated cholesterol levels.


Eligibility criteria: Inclusion Criteria:

* metabolic syndrome according to ATPIII criteria 3 of the following:

  * waist circumference \>88cm (in females) or \>102cm (in males)
  * triglycerides \>150mg/dl
  * HDL \<40 (50)mg/dl in males (females)
  * blood pressure\>130/85 or treatment for AHT
  * glucose \>110mg/dl

Exclusion Criteria:

* pregnancy
* treatment with cholesterol lowering drugs

Primary outcomes:
measure: LDL level
timeFrame: 2 months
measure: total cholesterol level
timeFrame: 2 months
measure: triglyceride level
timeFrame: 2 months
measure: HDL level
timeFrame: 2 months
Secondary outcomes:
measure: OxLDL
timeFrame: 2 months
measure: BMI
timeFrame: 2 months
measure: malondialdehyde (MDA)
timeFrame: 2 months
measure: 8-OH-deoxyguanosine (8-OHdG)
timeFrame: 2 months
measure: side effects
timeFrame: 2 months
measure: waist circumference
timeFrame: 2 months
Other outcomes:
Locations:
city: Antwerp
country: Belgium
facility: University of Antwerp
state: Belgie
Study officials:
References:
citation: Hermans N, Van der Auwera A, Breynaert A, Verlaet A, De Bruyne T, Van Gaal L, Pieters L, Verhoeven V. A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial. Trials. 2017 Jul 3;18(1):302. doi: 10.1186/s13063-017-2058-5.
citation: Verhoeven V, Van der Auwera A, Van Gaal L, Remmen R, Apers S, Stalpaert M, Wens J, Hermans N. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2015 Mar 10;15:52. doi: 10.1186/s12906-015-0576-9.
Clinical trial NCT00394862: Efficacy of Weekly Versus Daily Folic Acid Supplementation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Neural Tube Defects
Lead sponsor: Emory University
Sponsor class: OTHER
Collaborators: name: Centers for Disease Control and Prevention
First posted: 2006-11-01
Enrollment: 460
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 49
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Investigate the efficacy of weekly versus daily of folic acid supplementation on improving folate, vitamin B12,

Detailed description: 460 women of a rural community in the western highlands of Guatemala were recruited for participation in the double-blinded study led by Emory University and the Institute of Nutrition of Central America and Panama (INCAP). The women were randomly assigned one of 4 vitamin treatments containing different levels of folic acid, Vitamin B12, iron and zinc. The treatments were as follows:

1. weekly dose of folic acid at 5000ug, iron at 120 mg, zinc at 30mg, and B12 at 16.8 ug;
2. weekly dose of folic acid at 2800ug, iron at 120mg, zinc at 0mg and B12 at 16.8ug;
3. daily dose of folic acid at 400ug, iron at 60mg, zinc at 15mg, B12 at 2.4ug; and
4. daily dose of folic acid at 200ug, iron at 50mg, zinc at 0mg, and B12 at 2.4ug.

The women, aged 15-49, received the vitamins daily for 3 months. Anthropometric data and blood samples were taken at baseline and post-supplementation. The participants also completed a series of dietary interviews at baseline and post-intervention. No pregnant or lactating mothers were admitted into the study, nor severely anemic females. Blood samples were sent to the National Laboratory in Cuernavaca, Mexico, for analysis of serum folate levels.

Eligibility criteria: Inclusion Criteria:

* female
* aged 15-49

Exclusion Criteria:

* pregnant
* lactating less than 3 months
* severely anemic

Primary outcomes:
measure: serum folate level
measure: red blood cell folate
Secondary outcomes:
measure: homocysteine
measure: ferritin
measure: serum zinc
measure: serum B12
measure: blood pressure
measure: depression
Other outcomes:
Locations:
Study officials:
affiliation: Emory University
name: Reynaldo Martorell, PHD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04662762: A Nursing Intervention Program to Improve Therapeutic Adherence in Elderly People With Acute Myocardial Infarction
Official title: A Nursing Intervention Program Significantly Improves Therapeutic Adherence in Elderly People With Acute Myocardial Infarction: a Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Medication Adherence
Myocardial Infarction
Keywords: Elderly
Nursing
Lead sponsor: Hospital Universitari de Bellvitge
Sponsor class: OTHER
First posted: 2020-12-10
Enrollment: 160
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Patients were randomly assigned to a nursing intervention group or a usual care group (1:1).

Nonprobabilistic, consecutive sampling was carried out with random assignment of the study groups.
Primary purpose: PREVENTION

Brief summary: The objective of this study was to assess the impact of a nursing intervention on therapeutic adherence in elderly patients after acute myocardial infarction compared to a control group

Detailed description: A comprehensive geriatric assessment was performed during the first admission in all patients. Patients were randomly allocated to a nursing intervention group or a usual care group. In patients from the intervention group, a nursing intervention programme was performed 3 months after admission, based on education, support and patient monitoring to improve therapeutic adherence and a 6 month phone call. The main outcome measured was therapeutic adherence at 12 months, as defined by a combination of adherence measurement tools (Morisky-Green and Hayness-Sacket scales, attendance at visits and withdrawal of medication from the pharmacy). Therapeutic adherence was assessed by nurses blinded to the assignment group.

Eligibility criteria: Inclusion Criteria:

* Patients with STEMI aged 75 years or older underwent primary percutaneous coronary intervention (PCI)

Exclusion Criteria:

* Patients who refused to participate in the study
* Patients unable to perform geriatric assessment.
* Patients admitted to nursing homes or social health centres.

Primary outcomes:
measure: Number of patients with therapeutic adherence
timeFrame: 12 months after admission
Secondary outcomes:
measure: Rate of readmission,
timeFrame: During the 12 months after the admission
measure: Rate of visits to the emergency room
timeFrame: During the 12 months after the admission
measure: Rate of mortality
timeFrame: During the 12 months after the admission
Other outcomes:
Locations:
Study officials:
affiliation: Nurse
name: Elena Calvo, RN
role: PRINCIPAL_INVESTIGATOR
References:
citation: Calvo E, Izquierdo S, Castillo R, Cesar E, Domene G, Gomez AB, Guerrero C, Andreu-Periz L, Gomez-Hospital JA, Ariza-Sole A. Can an individualized adherence education program delivered by nurses improve therapeutic adherence in elderly people with acute myocardial infarction?: A randomized controlled study. Int J Nurs Stud. 2021 Aug;120:103975. doi: 10.1016/j.ijnurstu.2021.103975. Epub 2021 May 10.
Clinical trial NCT01537562: Intrauterine Contraception (IUC) After Medical Abortion
Official title: Early Versus Delayed Insertion of Intrauterine Contraception After Medical Abortion- a Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: IUC Insertion After Medical Abortion
Keywords: Copper IUD
LNG-IUS
intrauterine contraception
medical abortion
postabortion contraception
Lead sponsor: Karolinska Institutet
Sponsor class: OTHER
First posted: 2012-02-23
Enrollment: 129
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Today a large proportion of early abortions are medical, in accordance to the woman's choice. The main objective of the present study was to compare, in a randomised fashion, initiation of intrauterine contraception (IUC) at about 1 week versus 3 to 4 weeks post medical abortion with regard to expulsions and safety.


Eligibility criteria: Inclusion Criteria:

* age above 18
* elective medical abortion up to 9 weeks (63 days) of amenorrhea
* general good health and
* good understanding of Swedish language.

Exclusion Criteria:

* pathological pregnancies or abnormality of the uterus
* complications after the medical abortion, such as on-going pregnancy retained gestational sac or endometritis

Primary outcomes:
measure: Expulsion
timeFrame: 6 months after IUC insertion
Secondary outcomes:
measure: PID
timeFrame: within 6 months of IUC insertion
measure: serum hemoglobin
timeFrame: 4 weeks post IUC insertion
measure: Compliance
timeFrame: 6 months
measure: Bleeding patterns
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Stockholm
country: Sweden
facility: WHO centre, Karolinska University Hospital
Study officials:
affiliation: WHO centre, Dept of Women's and Childrens' Health, Div of Obstetrics and Gynecology, Karolinska Institutet/ Karolinska Univeristy Hospital
name: Kristina Gemzell Danielsson, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Saav I, Stephansson O, Gemzell-Danielsson K. Early versus delayed insertion of intrauterine contraception after medical abortion - a randomized controlled trial. PLoS One. 2012;7(11):e48948. doi: 10.1371/journal.pone.0048948. Epub 2012 Nov 14.
Clinical trial NCT02649062: Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals
Official title: Study of the Pharmacodynamics of NGM282 on Colonic Transit, Bile Acid Homeostasis, and Fecal Fat in Subjects With Functional Constipation and Healthy Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Functional Constipation
Lead sponsor: NGM Biopharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2016-01-07
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the effect of NGM282 on colonic transit, bile acid homeostasis, and fecal fat in subjects with functional constipation and healthy individuals.


Eligibility criteria: Inclusion Criteria:

* Functional constipation confirmed by modified Rome III criteria or Healthy Volunteer

Exclusion Criteria:

* Structural or metabolic diseases/conditions that affect the GI system
* Diagnosis of dyspepsia, IBS, or significant gastrointestinal symptoms

Primary outcomes:
measure: Effect on Colon Transit, as measured by the movement of food through the colon
timeFrame: 9 days
Secondary outcomes:
measure: Clinical Laboratory Assessments
timeFrame: 14 days
Other outcomes:
Locations:
city: Rochester
country: United States
facility: NGM Clinical Study Site 1
state: Minnesota
Study officials:
affiliation: NGM Biopharmaceuticals, Inc
name: Stephen J Rossi, PharmD
role: STUDY_DIRECTOR
References: